Medindia

X

Ventaira Pharmaceuticals Appoints Scientific Advisory Board

Tuesday, September 18, 2007 General News J E 4
Advertisement
COLUMBUS, Ohio, Sept. 17 Ventaira Pharmaceuticalsannounced today that the Company has formed a Scientific Advisory Board (SAB)consisting of a distinguished body of scientists and clinicians. The SAB willadvise the Company on the development of inhaled treatments to meet unmetneeds of cancer patients such as pain and nausea/emesis.

Ventaira expects to begin their clinical development program with theirlead compound late in the fourth quarter of 2007.

"We are privileged to work with this world-renowned group of experts whowill advise and guide us on our development decisions and strategies," statedLeslie Williams, President and CEO of Ventaira Pharmaceuticals. "The combinedexperiences of the advisory board will be invaluable as we embark on ourclinical development plan and establish the most efficient program."

Ventaira's Scientific Advisory Board

Edward Ball, M.D., is Professor of Medicine and Chief of the Division ofBlood and Bone Marrow Transplantation at the University of California, SanDiego (UCSD). He is also Co-Program Leader for Hematologic Malignancy at theRebecca and John Moores Cancer Center of UCSD. Dr. Ball's NIH-funded researchhas focused on the development and clinical application of monoclonalantibodies for the diagnosis and treatment of leukemia and cancer. Dr. Ballis also an expert in blood and marrow transplantation. Dr. Ball is one of theco-founders of Medarex, a company that uses antibody-based therapies to fightcancer and other debilitating diseases. Dr. Ball's experience in thetreatment of cancer and his accomplishments in the discovery and developmentof products have progressed into the clinic and marketplace. Dr. Ballreceived his M.D. degree at Case Western Reserve University in 1976, and hisHematology/Oncology fellowship at University Hospital of Cleveland andDartmouth University Medical Center.

Rudolf Brenneisen, Ph.D., is Professor of Phytochemistry and Pharmacognosyin the Department of Clinical Research at the University of Bern, Switzerland.Dr. Brenneisen's research focuses on the pharmacology and therapeuticpotential of cannabinoids and Cannabis and the chemistry, analyticalmethodology and pharmacology of natural and synthetic psychoactive substancesand medicinal plants. He has served as a consultant for the United NationsInternational Drug Control Program and for the Swiss Doping Commission. Dr.Brenneisen is a member of the Scientific Advisory Board of the Association ofCannabis as Medicine, a member of the Advisory Board of the "Journal ofCannabis as Therapeutics," and is affiliated with the Society for MedicinalPlant Research, the American Academy of Forensic Sciences, The InternationalAssociation of Forensic Toxicologists and the Society of ForensicToxicologists. Dr. Brenneisen received a M.S. in pharmaceutical sciences anda Ph.D. in phytochemistry and pharmacognosy from the University of Bern.

Steven Childers, Ph.D., is currently a Professor ofPhysiology/Pharmacology at Wake Forest University School of Medicine andDirector of a Drug Abuse Center, the Center for the NeurobiologicalInvestigation of Drug Abuse, funded by the National Institute on Drug Abuse,at Wake Forest University School of Medicine. His research interests includethe neuropharmacological mechanisms of a variety of drugs of abuse, includingcannabinoids, psychostimulants, and opioids, and has a particular interest inunderstanding the mechanisms of chronic drug actions in brain. He served onthe panel of scientific experts that generated the report on Marijuana andMedicine for the Institute of Medicine, National Academy of Sciences, in 1999.Dr. Childers received his B.S. in chemistry from the University of Texas atAustin, and his Ph.D. in physiological chemistry from the University ofWisconsin. He did postdoctoral training in the laboratory of Dr. SolomonSnyder at Johns Hopkins University, during the period whe
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
VLST Corp Names Consuelo M. Blosch, M.D., Vice Pre...
S
MEDai Impacts the World of Healthcare Underwriting